Biofrontera (NASDAQ:BFRI – Get Free Report) and Adherex Technologies (NASDAQ:FENC – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, dividends, profitability, valuation and risk.
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for Biofrontera and Adherex Technologies, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Biofrontera | 1 | 0 | 1 | 0 | 2.00 |
| Adherex Technologies | 1 | 1 | 4 | 1 | 2.71 |
Adherex Technologies has a consensus price target of $15.40, suggesting a potential upside of 69.23%. Given Adherex Technologies’ stronger consensus rating and higher possible upside, analysts clearly believe Adherex Technologies is more favorable than Biofrontera.
Volatility & Risk
Earnings and Valuation
This table compares Biofrontera and Adherex Technologies”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Biofrontera | $41.71 million | 0.31 | -$10.54 million | ($0.97) | -1.03 |
| Adherex Technologies | $44.64 million | 7.11 | -$9.74 million | ($0.29) | -31.38 |
Adherex Technologies has higher revenue and earnings than Biofrontera. Adherex Technologies is trading at a lower price-to-earnings ratio than Biofrontera, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
10.1% of Biofrontera shares are held by institutional investors. Comparatively, 55.5% of Adherex Technologies shares are held by institutional investors. 8.1% of Biofrontera shares are held by company insiders. Comparatively, 10.7% of Adherex Technologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Profitability
This table compares Biofrontera and Adherex Technologies’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Biofrontera | -25.66% | -515.34% | -53.91% |
| Adherex Technologies | -17.12% | -43.87% | -11.35% |
Summary
Adherex Technologies beats Biofrontera on 14 of the 15 factors compared between the two stocks.
About Biofrontera
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
About Adherex Technologies
Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.
Receive News & Ratings for Biofrontera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biofrontera and related companies with MarketBeat.com's FREE daily email newsletter.
